GERMANTOWN, Md., Nov. 18, 2022 (GLOBE NEWSWIRE) — TeraImmune, Inc., a biotechnology company focused on the discovery and development of novel Treg-based cell therapies for autoimmune diseases, today announced that it has announced that it has released data on the TREGable of ™ technology was presented at the Human Cell Atlas Asia (HCA Asia) 2022 meeting held November 3-4 in Bangkok, Thailand.
Regulatory T cells (Treg) are a small but important subset of CD4+ T cells and play a role in maintaining immune homeostasis. Through research sponsored by this company, researchers have characterized, co-cultured, and expanded Tregs using 25-mer DNA oligonucleotides (named TREGable™ technology). The identified novel expanded Treg subclusters may be potential clinical therapies for autoimmune diseases. Researchers have discovered a new eeTreg and demonstrated that this Treg is a fully activated Treg.
In this study, a comparison of single-cell RNA-sequencing (scRNA-seq) and ATAC-sequencing between isolated Treg cells and TREGable™ expanded Treg (eTreg) cells allowed researchers to identify novel eTreg-enriched Treg (eeTreg). Expression of both naive and effector marker genes was simultaneously high. A new algorithm was also developed to infer the activity of Treg master transcription factors (TFs), and epigenetic properties were analyzed using TF ChIP-seq data. These master TFs were more activated in the eeTreg compared to other his Tregs, contributing to their stability during that time. ex vivo Expansion period.
Dr. Yong Chan Kim, CEO of TeraImmune, said: “Our advanced TCR/CAR Treg platform has demonstrated both natural Tregs isolated from patients (TREGable™) and induced Tregs converted from patient Teff cells without loss of suppressive activity (TREGing™). This data provides new evidence of the efficacy of TeraImmune’s TREGable/TREGing technology in the stable production of functional Treg cells for cell therapy.We are excited to share our TREGable technology. I look forward to preparing the manuscript for publication in a scientific journal.”
Details of the onsite poster presentation
Title: Simultaneous epigenetic and gene expression profiling of human regulatory T cells at the single-cell level identifies novel effector regulatory T cells
Presenter/First Author: Hyun Je Kim, MD, PhD, Department of Microbiology and Immunology, Seoul National University College of Medicine
Abstract number: #20
Session: Technology and Analytics
About HCA Asia
The HCA Asia Conference aims to bring researchers together to share updates and insights, broaden community representation across the Asia-Pacific region, and enhance scientific impact regionally and globally.
About Terai Mune Co., Ltd.
TeraImmune, Inc. is a biotechnology company developing innovative immune cell therapies. The Company has developed a Dual Tregs that consists of both natural regulatory T cells (Treg) isolated from a patient (TREGable™) and induced Tregs (TREGing™) converted from the patient’s T effector (Teff) cells Leveraging manufacturing platforms. Its Treg platform technology is designed for conditions that suppress unwanted immune responses. We have expanded our pipeline to include cord blood-derived allogeneic or off-the-shelf Tregs for the treatment of skin conditions such as atopic dermatitis. Enhanced Treg selectivity through target-specific receptors can suppress unwanted immune responses without side effects in patients with autoimmune diseases.
Investor inquiry
Westwicke, ICR Company
Stephanie Carrington
Stephanie.carrington@westwicke.com
646-277-1282
